Annexin Proteins: Novel Promising Targets for Anticancer Drug Development

Abstract

Intracellular Ca 2+ signaling and Ca 2+ homeostasis have long been an important subject area of cell biology. Several intracellular Ca 2+ binding proteins have been demonstrated until now, and among these, annexins are characterized by their ability to interact with membrane phospholipids and they form an evolutionary conserved multigene family with the members being expressed throughout animal and plant kingdoms. Annexin proteins are defined by different structural and biochemical criteria, and this multigene family has several biological features. In certain clinical conditions, the alterations on the localization or expression levels of annexin proteins are considered as the causes of pathological results and/or sequelae of disease. So, annexin proteins are indirectly linked to severe human diseases such as cardiovascular disease and cancer. Since annexin proteins are known to play roles in cancer, the researches are focused on defining the clinical significance of certain annexin proteins in cancer development and by the way anticancer treatments in the last decades. This chapter presents detailed information about annexin proteins and the studies on anticancer drug development targeting certain annexins. The studies denominate that targeting of certain annexin proteins reduces tumorigenesis and therapeutic resistance. So, annexin proteins have growing importance for anticancer drug development.

Fluorescent Lipo-Beads for the Sensitive Detection of Phospholipase A2 and Its Inhibitors

“…Annexins have emerged as disease biomarkers for cancer, diabetes, and inflammatory diseases. − They are a family of proteins that binds to phospholipids and are also known to inhibit PLA 2 activity. ,, In this work, we performed preliminary studies on annexin detection as another proof of concept for the study using lipo-beads for PLA 2 inhibition. Our initial ANXA-3 test with anionic lipo-beads generated a moderate result (Figure S7).…”